Annual Report 2018 Active Biotech AB (publ)
April 26 2019 - 5:00AM
PRESS RELEASE
Active Biotech's Annual Report 2018 is now
available for download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English
version will be available within short.
Download as PDF
Lund, April 26, 2019
Active Biotech AB (publ)
Helén Tuvesson
CEO
For further information, please
contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA (naptumumab), an immunotherapy, in development for
cancer indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the
Securities Markets Act. The information was submitted for
publication at 11.00 a.m CET on April 26,
2019.
Annual Report 2018 Active Biotech
AB (publ)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024